Breast Cancer Drug Promising in Phase 3 Trial

WEDNESDAY, Aug. 15, 2018 (HealthDay News) — For women with advanced breast cancer who carry the BRCA1 and BRCA2 gene mutations, an experimental drug could improve survival, a new study suggests. The BRCA mutations are linked with a greater risk for aggressive breast and ovarian cancer. The drug, talazoparib, works by blocking an enzyme called…

Triple-Negative Breast Cancer Genes ID'd

WEDNESDAY, Aug. 8, 2018 (HealthDay News) — More genes associated with an increased risk of triple-negative breast cancer have been identified by researchers. Until now, only mutations in the BRCA1 gene have been linked with this type of breast cancer. “Triple-negative breast cancer is an aggressive type of cancer that cannot be treated using targeted…